Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin’s lymphoma: A case report
고전적 호지킨 림프종에 대한 A+AVD 치료 중 SARS-CoV-2 감염의 장기간 지속: 증례 보고
Case Reports
[키워드] A+AVD therapy (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine)
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
added
afebrile
antiviral therapy
Asymptomatic
brentuximab vedotin
Case report
Chain Reaction
chest X-ray
Ciclesonide
classical
Classical Hodgkin lymphoma
Comorbidities
complaint
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patient
COVID-19 patients
criteria
dacarbazine
diagnosed with COVID-19
discharge
discharged
disease
Doxorubicin
Favipiravir
Fever
Health Organization
Hematologic malignancy
Hodgkin lymphoma
hospital
Infection
mandatory
opacity
Patient
patient population
PCR
PCR test
PCR tests
persistence
polymerase chain
polymerase chain reaction
positive
Prolonged
remained
Remdesivir
Remdesivir, RT-PCR
respiratory
respiratory status
RT-PCR
SARS-CoV-2
SARS-COV-2 infection
severe acute respiratory syndrome Coronavirus
the patient
therapy
Treatment
vinblastine
Viral
virus
WHO
World Health Organization
worsened
[DOI] 10.1016/j.currproblcancer.2021.100739 PMC 바로가기 [Article Type] Case Reports
[DOI] 10.1016/j.currproblcancer.2021.100739 PMC 바로가기 [Article Type] Case Reports